Search Results - "Christoph Spinner"

Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study by Lahmer, Tobias, Kriescher, Silja, Herner, Alexander, Rothe, Kathrin, Spinner, Christoph D, Schneider, Jochen, Mayer, Ulrich, Neuenhahn, Michael, Hoffmann, Dieter, Geisler, Fabian, Heim, Markus, Schneider, Gerhard, Schmid, Roland M, Huber, Wolfgang, Rasch, Sebastian

“…Superinfections, including invasive pulmonary aspergillosis (IPA), are well-known complications of critically ill patients with severe viral pneumonia. Aim of…”
Get full text

Clinical and virological features of first human monkeypox cases in Germany by Noe, Sebastian, Zange, Sabine, Seilmaier, Michael, Antwerpen, Markus H., Fenzl, Thomas, Schneider, Jochen, Spinner, Christoph D., Bugert, Joachim J., Wendtner, Clemens-Martin, Wölfel, Roman

“…Background Monkeypox is a zoonotic orthopoxvirus infection endemic in central and western Africa. In May 2022, human monkeypox infections including…”
Get full text

Declining COVID-19 morbidity and case fatality in Germany: the pandemic end? by Dennler, Ulf, Geisler, Fabian, Spinner, Christoph D.

Get full text

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 by Goldman, Jason D, Lye, David C.B, Hui, David S, Marks, Kristen M, Bruno, Raffaele, Montejano, Rocio, Spinner, Christoph D, Galli, Massimo, Ahn, Mi-Young, Nahass, Ronald G, Chen, Yao-Shen, SenGupta, Devi, Hyland, Robert H, Osinusi, Anu O, Cao, Huyen, Blair, Christiana, Wei, Xuelian, Gaggar, Anuj, Brainard, Diana M, Towner, William J, Muñoz, Jose, Mullane, Kathleen M, Marty, Francisco M, Tashima, Karen T, Diaz, George, Subramanian, Aruna

“…A randomized trial comparing a 5-day course of intravenous remdesivir with a 10-day course in patients with Covid-19 pneumonia and hypoxemia who were not yet…”
Get full text

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial by Spinner, Christoph D, Gottlieb, Robert L, Criner, Gerard J, Arribas López, José Ramón, Cattelan, Anna Maria, Soriano Viladomiu, Alex, Ogbuagu, Onyema, Malhotra, Prashant, Mullane, Kathleen M, Castagna, Antonella, Chai, Louis Yi Ann, Roestenberg, Meta, Tsang, Owen Tak Yin, Bernasconi, Enos, Le Turnier, Paul, Chang, Shan-Chwen, SenGupta, Devi, Hyland, Robert H, Osinusi, Anu O, Cao, Huyen, Blair, Christiana, Wang, Hongyuan, Gaggar, Anuj, Brainard, Diana M, McPhail, Mark J, Bhagani, Sanjay, Ahn, Mi Young, Sanyal, Arun J, Huhn, Gregory, Marty, Francisco M

“…IMPORTANCE: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect…”
Get full text

Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV by Hoffmann, Christian, Casado, José L., Härter, Georg, Vizcarra, Pilar, Moreno, Ana, Cattaneo, Dario, Meraviglia, Paola, Spinner, Christoph D., Schabaz, Farhad, Grunwald, Stephan, Gervasoni, Cristina

“…Objectives A prior T cell depletion induced by HIV infection may carry deleterious consequences in the current COVID‐19 pandemic. Clinical data on patients…”
Get full text

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients by Härter, Georg, Spinner, Christoph D., Roider, Julia, Bickel, Markus, Krznaric, Ivanka, Grunwald, Stephan, Schabaz, Farhad, Gillor, Daniel, Postel, Nils, Mueller, Matthias C., Müller, Markus, Römer, Katja, Schewe, Knud, Hoffmann, Christian

“…Introduction Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH…”
Get full text

HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans by Spinner, Christoph D., Boesecke, Christoph, Zink, Alexander, Jessen, Heiko, Stellbrink, Hans-Jürgen, Rockstroh, Jürgen Kurt, Esser, Stefan

“…Purpose Despite established HIV prevention strategies and broadly available diagnostic strategies in developed western countries, rates of HIV new infections…”
Get full text

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study by Deterding, Katja, MD, Spinner, Christoph D, MD, Schott, Eckart, Prof, Welzel, Tania M, MD, Gerken, Guido, Prof, Klinker, Hartwig, Prof, Spengler, Ulrich, Prof, Wiegand, Johannes, MD, zur Wiesch, Julian Schulze, MD, Pathil, Anita, MD, Cornberg, Markus, Prof, Umgelter, Andreas, MD, Zöllner, Caroline, MD, Zeuzem, Stefan, Prof, Papkalla, Armin, PhD, Weber, Kristina, PhD, Hardtke, Svenja, PhD, von der Leyen, Heiko, Prof, Koch, Armin, Prof, von Witzendorff, Dorothee, PhD, Manns, Michael P, Prof, Wedemeyer, Heiner, Prof

“…Summary Background Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent…”
Get full text

Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship by Rothe, Kathrin, Feihl, Susanne, Schneider, Jochen, Wallnöfer, Fabian, Wurst, Milena, Lukas, Marina, Treiber, Matthias, Lahmer, Tobias, Heim, Markus, Dommasch, Michael, Waschulzik, Birgit, Zink, Alexander, Querbach, Christiane, Busch, Dirk H., Schmid, Roland M., Schneider, Gerhard, Spinner, Christoph D.

“…The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. Bacterial…”
Get full text

SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype by Bongiovanni, Dario, Klug, Melissa, Lazareva, Olga, Weidlich, Simon, Biasi, Marina, Ursu, Simona, Warth, Sarah, Buske, Christian, Lukas, Marina, Spinner, Christoph D., Scheidt, Moritz von, Condorelli, Gianluigi, Baumbach, Jan, Laugwitz, Karl-Ludwig, List, Markus, Bernlochner, Isabell

“…Novel coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state, characterized by abnormal coagulation parameters and by increased…”
Get full text

Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned by Dölken, Lars, Stich, August, Spinner, Christoph D

“…After more than one year of the COVID-19 pandemic, antiviral treatment options against SARS-CoV-2 are still severely limited. High hopes that had initially…”
Get full text

A diagnostic algorithm for detection of urinary tract infections in hospitalized patients with bacteriuria: The "Triple F" approach supported by Procalcitonin and paired blood and urine cultures by Rothe, Kathrin, Spinner, Christoph D, Waschulzik, Birgit, Janke, Christian, Schneider, Jochen, Schneider, Heike, Braitsch, Krischan, Smith, Christopher, Schmid, Roland M, Busch, Dirk H, Katchanov, Juri

“…For acute medicine physicians, distinguishing between asymptomatic bacteriuria (ABU) and clinically relevant urinary tract infections (UTI) is challenging,…”
Get full text

Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany by Hoffmann, Christian, Jessen, Heiko, Wyen, Christoph, Grunwald, Stephan, Noe, Sebastian, Teichmann, Jörn, Krauss, Anja‐Sophie, Kolarikal, Henning, Scholten, Stefan, Schuler, Christoph, Bickel, Markus, Roll, Clemens, Kreckel, Peter, Köppe, Siegfried, Straub, Matthias, Klausen, Gerd, Lenz, Johannes, Esser, Stefan, Jensen, Björn, Rausch, Michael, Unger, Stefan, Pauli, Ramona, Härter, Georg, Müller, Matthias, Masuhr, Anja, Schäfer, Guido, Seybold, Ulrich, Schellberg, Sven, Schneider, Jochen, Monin, Malte Benedikt, Wolf, Eva, Spinner, Christoph D., Boesecke, Christoph

“…Background Since May 2022, increasing numbers of monkeypox virus (MPXV) infections have been reported from across Europe and North America. Studies, mainly…”
Get full text

CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients by Weber, Simone, Kehl, Victoria, Erber, Johanna, Wagner, Karolin I, Jetzlsperger, Ana-Marija, Burrell, Teresa, Schober, Kilian, Schommers, Philipp, Augustin, Max, Crowell, Claudia S, Gerhard, Markus, Winter, Christof, Moosmann, Andreas, Spinner, Christoph D, Protzer, Ulrike, Hoffmann, Dieter, D'Ippolito, Elvira, Busch, Dirk H

“…COVID-19 has so far affected more than 250 million individuals worldwide, causing more than 5 million deaths. Several risk factors for severe disease have been…”
Get full text

Strategies for increasing diagnostic yield of community-onset bacteraemia within the emergency department: A retrospective study by Rothe, Kathrin, Spinner, Christoph D, Ott, Armin, Querbach, Christiane, Dommasch, Michael, Aldrich, Cassandra, Gebhardt, Friedemann, Schneider, Jochen, Schmid, Roland M, Busch, Dirk H, Katchanov, Juri

“…Bloodstream infections (BSI) are associated with high mortality. Therefore, reliable methods of detection are of paramount importance. Efficient strategies to…”
Get full text

Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report by Erber, Johanna, Weidlich, Simon, Tschaikowsky, Tristan, Rothe, Kathrin, Schmid, Roland M, Schneider, Jochen, Spinner, Christoph D

“…Mycobacterium fortuitum complex is a group of rapidly growing nontuberculous mycobacteria (NTM) associated with skin and soft-tissue infections after surgery…”
Get full text

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19 by Hirsch, Caroline, Park, Yun Soo, Piechotta, Vanessa, Chai, Khai Li, Estcourt, Lise J, Monsef, Ina, Salomon, Susanne, Wood, Erica M, So-Osman, Cynthia, McQuilten, Zoe, Spinner, Christoph D, Malin, Jakob J, Stegemann, Miriam, Skoetz, Nicole, Kreuzberger, Nina

“…Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells of an infected host. They are being investigated as potential…”
Get more information

A Moderate Case of COVID-19 Viral Pneumonia During the SARS-CoV-2 Pandemic by Spinner, Christoph D, Schuldt, Alexander, Schuster, Jörg

Get full text

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254 by Spinner, Christoph D, Felizarta, Franco, Rizzardini, Giuliano, Philibert, Patrick, Mitha, Essack, Domingo, Pere, Stephan, Christoph J, DeGrosky, Michelle, Bainbridge, Veronica, Zhan, Joyce, Dumitrescu, Teodora Pene, Jeffrey, Jerry L, Xu, Jianfeng, Halliday, Fiona, Gan, Jianjun, Johnson, Mark, Gartland, Martin, Joshi, Samit R, Lataillade, Max

“…GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily…”
Get full text